Korean Tickers
KRX in English

Home Markets Stocks Financials Guide

Newsfeed Insights Earnings Broker research

Korean Tickers
KRX in English

Home Markets Stocks Financials Guide

Newsfeed Insights Earnings Broker research

Market Pulse

Daily · Nov 5, 2026 · data.go.kr + ECOS

KOSPI

5,383.80

-300.00 (-5.28%)

KOSDAQ

678.41

-36.54 (-5.11%)

KOSPI 200

837.78

-51.47 (-5.79%)

USD/KRW

1,342.10

Home›Reports›009420

009420KOSPI·Mar 21, 2025

Batoclimab phase 3 trial data announced

HANALL BIOPHARMA CO. Co., Ltd.Mirae Asset SecuritiesMihwa Seo

Read original PDF ↗

HB

Source: Mirae Asset Securities
Type: Company Analysis
Language: English
Rating: Buy
Target price: -
Collected: May 06, 2026

The full report is published by Mirae Asset Securities. Korean Tickers provides its source link and metadata.

More research on 009420

Imeroprubart��s best-in-class potential remains intactMirae Asset Securities · May 21, 2026 IMVT-1402 to regain focus from 2H26Mirae Asset Securities · Mar 13, 2026 Promising batoclimab results heighten expectations for IMVT-1402Mirae Asset Securities · Sep 25, 2025 1Q25 to be a key inflection pointMirae Asset Securities · Feb 27, 2025

Advertisement

Korean Tickers·Research reference for Korean listed companies.

Prices use KIS quote snapshots with data.go.kr daily fallback. Financials use DART; macro data uses ECOS.·Market data is informational and not investment advice.

KIS snapshots are refreshed every 30 minutes and are not a streaming quote feed.·Sources

Terms Refunds Disclaimer Privacy